Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ORIC-533 |
Synonyms | |
Therapy Description |
ORIC-533 inhibits CD73, which leads to decreased adenosine production and potentially results in enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 2074). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ORIC-533 | ORIC 533|ORIC533 | ORIC-533 inhibits CD73, which leads to decreased adenosine production and potentially results in enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 2074). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05227144 | Phase I | ORIC-533 | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | CAN | 0 |